Form 6-K NOVO NORDISK A S For: Mar 31

Go back to Form 6-K NOVO NORDISK A S For: Mar 31

BofA Securities Comments on Novo Nordisk (NVO)

May 3, 2024 5:55 AM EDT

BofA Securities analyst Sachin Jain reiterated a Buy rating and $147.00 price target on Novo Nordisk (NYSE: NVO)

The analyst comments "Key takes from 1Q results: 1) 1Q24 adjusted EPS DKK5.68 +29%, 8% ahead of consensus, on 2% sales beat and operating margin 300bps ahead, mainly on S&D, offset by lower OOI (-DKK568m vs +DKK33m,... More